ART Advanced Research Technologies Inc.

ART Advanced Research Technologies Inc.

March 30, 2007 11:10 ET

ART Receives Genesis Award for Entrepreneurship in Health Technology at BIOMEDEX Conference

MONTREAL, CANADA--(CCNMatthews - March 30, 2007) - ART Advanced Research Technologies Inc. ("ART") (TSX:ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, is proud to announce it has received the Health Technology Entrepreneurship Award at the 7th edition of the Genesis Awards Gala held yesterday as part of the BIOMEDEX 2007 conference-exhibition. The Gala pays tribute to the people and companies that have played a crucial role in the growth of Quebec's biotechnology, health technology and life sciences industries. This is the second time that ART has been honoured by this award, which was previously presented to the Company in 2004.

"We are thrilled by this recognition which demonstrates the talent and passion of our entire team," stated Sebastien Gignac, President and CEO of ART. "It is also a testimony to the leadership ART has demonstrated over the years in the field of optical imaging," concluded Mr. Gignac.

With this award, ART was honored for outstanding growth results due to the leadership of its management team. Its market leadership has been shown by its sales revenue progress over the past years in the emerging field of pre-clinical imaging, the top rate employees it recruits and its ability to attract investments. ART has also been recognized to be a company led by business executives who are renowned for their growth-oriented management style and leadership, for the strategic alliances it has made and for the quality of its research team. ART was found to be competitive in its line of business and successful internationally, owing to the Company's global strategic approach.

The Genesis Awards Gala is the most prestigious event of its kind in Quebec's biotechnology, health technology and life sciences industry. The Gala seeks to pay tribute to the dedicated work done by the companies, groups and individuals who have made a significant contribution to the development of biotechnology, the life sciences and health technology in Quebec. Initiated by BIOQuebec in 2001, it recognizes outstanding achievements of companies in the categories of Entrepreneurship, Innovation and Technology Transfer and honours personalities who have played a key role in the growth of Quebec's life sciences industry.

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. eXplore Optix™, an optical molecular imaging device designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is distributed by GE Healthcare and is used by industry and academic leaders worldwide. SoftScan®, an optical medical imaging device, is designed to improve the diagnosis and treatment of breast cancer. ART is commercializing these products in a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. Finally, the Fenestra™ line of molecular imaging contrast products provide image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. ART's shares are listed on the TSX under the ticker symbol ARA. For more information on ART, visit our website at .

This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in the Management Proxy Circular of ART dated October 24, 2006, available on SEDAR ( under the profile of "ART Advanced Research Technologies Inc. (old)" (ART's predecessor issuer).

Contact Information